Keros Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Keros Therapeutics

04/05/2023 22:17

* Keros Therapeutics Inc  KROS.OQ  reported a quarterly
adjusted
loss of $1.26​​ per share for the quarter ended in March. The
mean expectation of seven analysts for the quarter was for a
loss of $1.12 per share.
    * Reported revenue was zero​; analysts expected $216.67
thousand. 
    * Keros Therapeutics Inc's reported EPS for the quarter was
a loss
of $1.26​.
    * The mean earnings estimate of analysts had fallen by
about 2.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Keros Therapeutics Inc shares had risen by 6.1% this
quarter and
lost 5.7% so far this year.
    * The company reported a quarterly loss of $35.8 million.
    * Wall Street's median 12-month price target for Keros
Therapeutics Inc is $100.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 09:16 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -1.12          -1.26          Missed
 Dec. 31 2022      -1.10          -1.09          Beat
 Sep. 30 2022      -1.23          -0.92          Beat
 Jun. 30 2022      -1.06          -1.13          Missed